— Avid Bioservices (NASDAQ: CDMO) reported a second-quarter 2020 loss of $0.03 per share versus a loss of $0.05 per share expected.
— Revenue soared by 80% to $18.3 million versus $14.25 million expected. This was driven by an increase in the number of in-process and completed manufacturing runs as a result of growing demand from a more diversified client base.
— As of October 31, 2019, revenue backlog was about $52 million, a decrease of 16% as compared to the first quarter of fiscal 2020. The company expects to recognize the majority of this backlog within the next twelve months.
— The gross margin increased to 18% from 3% in the prior-year quarter. This was primarily attributed to the increased number of manufacturing runs.
— Looking ahead into fiscal 2020, the company confirmed its revenue outlook in the range of $64 million to $67 million. In contrast, analysts expect revenue of $65.38 million for the full year.
— The company launched expanded process development (PD) facilities and services. Also, it expanded the scope of work with multiple existing customers to increase the number of manufacturing batches and/or scale of production.
Most Popular
HD Stock: What’s in store for Home Depot after record second quarter
Home improvement is one of the top activities that kept Americans busy during the pandemic, a trend that enabled The Home Depot, Inc. (NYSE: HD) to beat the crisis and
Target (TGT) stock drops after Q2 earnings miss estimates; revenue up 4%
Department store chain Target Corporation (NYSE: TGT) reported a sharp decline in adjusted earnings for the second quarter of 2022, despite an increase in net sales. The bottom line also fell
Amazon (AMZN) stock remains a good bet despite poor results. Here’s why
Amazon.com, Inc. (NASDAQ: AMZN) became an inspiration for other players in the eCommerce sector as the online retailer successfully channelized its resources to tap into the spike in demand for
